The treatment of leukemia remains the success story of cancer. The patients with acute lymphoblastic leukemia survive longer and longer, with the rates of long time remission of over 80% in children and 30-40% in adults. Therefore, increased attention is given to diagnose and prevent central nervous system (CNS) complications, not only in order to increase the survival, but also in order to pre...

Patients who are immunocompromised by diseases such as human immunodeficiency virus (HIV) infection are more prone to develop some malignancies such as Kaposi's sarcoma and central nervous system (CNS) lymphomas. Historically, anal squamous cell carcinoma (SCC) was also included on the list as an acquired immunodeficiency syndrome (AIDs)-defining cancer.  Similarly, compromised immune disorders...

background and purpose: over the past years, the role of fungi as a cause of nosocomial infections in hospitalized patients has been accentuated. candida species constitute an important group of fungi causing diseases in immunocompromised patients. oropharyngeal candidiasis continues to be a prevalent infection in immunodeficient patients. in this study, we aimed to determine the incidence of o...

splenic infarction occurs due to occlusion of splenic vessels that leads to splenic tissue ischemia and necrosis. there are several reports regarding splenic infarction in patients with acute myelogenous leukemia (aml). herein, we report a case of acute promyelocytic anemia (aml-m3) who presented with abdominal pain and splenic infarction.

Traditionally, cytotoxic drugs have played a limited role in the treatment of brain tumors, but important advances in chemotherapy have occurred during the past decade. Certain central nervous system (CNS) malignancies are remarkably chemosensitive. These include primary CNS lymphoma, medulloblastoma, oligodendroglioma, and intracranial germ-cell tumors. This review focuses on advances in the c...

The role of immunotherapy in treatment of brain metastases is unknown because most trials exclude patients with active brain lesions. As new immunomodulating agents gain approval for many malignancies, it is important to know if they have unique effects in the central nervous system (CNS). Here, we present a case of a patient with progressing brain metastases treated with a single cycle of pemb...

Microtubules have been among the most successful targets in anticancer therapy and a large number of microtubule-targeting agents (MTAs) are in various stages of clinical development for the treatment of several malignancies. Given that injury and diseases in the central nervous system (CNS) are accompanied by acute or chronic disruption of the structural integrity of neurons and that microtubu...

Tumours of the central nervous system (CNS) are the second most common childhood malignant diseases after hematological malignancies. The incidence is similar in the different developed countries: in Europe is 29.9/million (1978-1997), in USA 30.7/million (1992-2006). However, the highest incidence is registered in Hungary and the Scandinavian countries. In Hungary the incidence was 37.41/milli...

Cutaneous immune-related adverse events (cirAEs) are the most common toxicities to occur in setting of immune checkpoint inhibitor (ICI) therapy. This multi-institutional retrospective cohort study examines relationship between cancer type, tumor tissue and cirAE development. Using data from Mass General Brigham Dana-Farber, we identified 3,711 ICI recipients, whom 672 developed cirAEs reviewed...

Recently, we described a new animal model of CNS primitive neuroectodermal tumors (CNS-PNET), which was generated by orthotopic transplantation of human Radial Glial (RG) cells into NOD-SCID mice's brain sub-ventricular zone. In the current study we conducted comprehensive RNA-Seq analyses to gain insights on the mechanisms underlying tumorigenesis in this mouse model of CNS-PNET. Here we show ...